The global cholera vaccines market is anticipated to grow significantly during the forecast period due to rising government initiatives in immunization programs, and the growing incidence of cholera, particularly in developing countries in Asia and Africa, which will drive the growth of the cholera vaccines market globally.
The report titled "Cholera Vaccines Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall Cholera Vaccines market, along with the market's size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on the type of product and different geographical regions.
Geographically, the global cholera vaccine market is studied for the following regional markets:
North America
U.S.
Canada
Europe
U.K.
Germany
Rest of Europe
Asia-Pacific
China
Japan
Rest of Asia Pacific
Latin America
Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global cholera vaccine market. Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive scenario of the global cholera vaccines market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global cholera vaccine market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global cholera vaccines market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.
Based on product type, the global cholera vaccine market is segmented as follows:
Dukoral
Shanchol
Vaxchora
Others
Cholera is an infectious disease that causes severe, watery diarrhea, which can even lead to death if left untreated. The burden of cholera remains high globally, particularly in resource-poor countries in Asia and Africa. According to the World Health Organization (WHO), there are roughly 1.4 to 4.0 million cholera cases and 21,000 to 143,000 deaths worldwide each year due to cholera. There are different types of vaccines available on the market, such as the killed whole cell vaccine with cholera toxin B subunit, the Vietnamese killed whole cell-only vaccine, modified killed whole cell-only vaccines, and live oral vaccines such as CVD-103-HgR. In the base year 2016, Dukoral was a major revenue-generating segment as it is prequalified by the World Health Organization (WHO) and has been licensed in more than 60 countries. It is also preferably used in the treatment of diarrhea caused by Vibrio cholera and heat-labile toxin-producing enterotoxigenic Escherichia coli (ETEC). These are the prime factors driving the growth of the Dukoral market globally. It is estimated that the recently approved (June 2016) Vaxchora will show significant growth during the forecast period due to its safety, availability, and effectiveness, which would be expected to drive the market's growth during the forecast period. Vaxchora is the only vaccine available in the United States for protection against cholera and the only single-dose vaccine for cholera currently licensed anywhere in the world.
The global cholera vaccines market is divided into three segments for the purposes of this study:
North America
Europe
Asia Pacific
Latin America (LATAM)
Middle East and Africa (MEA)
According to the World Health Organization (WHO), cholera represents an estimated burden of 1.4 to 4.0 million cases and 21,000 to 143,000 deaths per year worldwide. For the purposes of this study, the global cholera market is divided into five regions: North America, Europe, Asia Pacific, LATAM, and MEA. North America is expected to dominate the cholera market during the forecast period due to higher healthcare awareness among the general population, government initiatives in treatment and awareness programs, the higher cost of vaccines, and the presence of key manufacturers, which will drive the market. Centers for Disease Control and Prevention (CDC) recommendations for travelers to cholera-affected regions would fuel market growth in the United States. On the other hand, Asia Pacific is currently dominating the cholera vaccines market due to increasing awareness of immunization, a higher number of targeted populations, and government initiatives in the awareness program that are primarily driving the market growth in Asia Pacific.
Frequently Asked Questions:
The market for Cholera Vaccines is expected to reach US$ 234.5 Mn in 2025.
The Cholera Vaccines market is expected to see significant CAGR growth over the coming years, at 15.8%.
The report is forecasted from 2017-2025.
The base year of this report is 2016.
Astellas Pharma, Inc.,Sonofi,PaxVax,Valneva SE,Eubiologics are some of the major players in the global market.
